www.StockMarketingInc.com: Amazing News!! You Will Know First If You Sign Up For Our Newsletter!! QPRJ "Quadra's Subsidiary Signs Sales Order for $420,000 With Fanta"

STOCK MARKETING INC PRESENTS :

(OTCBB: QPRJ - Quadra Projects Inc.)

(NASDAQ: CPWR - Compuware Corp.)

(NASDAQ: CREE - Cree, Inc.)

(NASDAQ: CTXS - Citrix Systems, Inc.)

(NASDAQ: CYTK - Cytokinetics, Inc.)

(NASDAQ: DGII - Digi International Inc.)

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: QPRJ - Quadra Projects Inc.)

LATEST NEWS!!

Quadra's Subsidiary Signs Sales Order for $420,000 With Fanta

LAS VEGAS, NV, Nov 09, 2009 -- QUADRA PROJECTS INC. ("Quadra" or the "Company") (OTCBB: QPRJ), announced today that its wholly owned subsidiary, Quadra Energy Systems Inc. (QES), a Belize corporation, signed a sales agreement with its distributor Fanta International Enterprises (Canada) Inc. (Fanta) for the sale of a QES2000 Utility Unit and the Company's technical team has commenced manufacturing with an anticipated delivery date of January 15th 2010. The purchase price for the sales agreement is $420,000 USD.

Mr. Stephen Leung, President of Fanta, advised this order is the precursor of an additional order for 2 QES2000 conversion units generating anticipated revenues of $2,600,000 USD for the Company. Mr. Leung also confirmed that on his recent trip to China, he met with senior government officials and corporate executives all of whom were very enthusiastic about the QES2000 System and expressed interest in acquiring the QES2000 Systems, it being one of the solutions for solving the environmental problems caused by waste.

Further, Mr. Leung confirmed the completion of its service and parts center and establishment of its sales team to support the anticipated sale of many QES2000 waste to energy conversion units throughout China.

The QES2000System is patented and Management of the Company is of the opinion that it is the most advanced prolysis and gasification system in the world, specifically designed to convert all organic waste (including used tires, plastic waste and municipal waste etc.) to valuable by-products such as N220 carbon black, biochar fertilizer, etc. and/or fuel oil or fuel gas for the production of electrical power, without any measurable environmental pollution or ash to be land filled. The QES2000 System is designed to meet the Global challenges of the 21st Century wherein natural resources are being exhausted, the petroleum industry is unstable and uncertain in terms of cost and supply and the world is seeing a degradation of the Global environment.

On account of the affordability of the QES2000 System, and the creation of significant revenue streams from the by-products, the return on investment is much greater than other competitive systems.

Initially, the Company will focus its expansion initiatives in Asia, primarily in the fast growth countries of China, India and South-East Asian countries.

About QUADRA PROJECTS INC.

QUADRA PROJECTS INC. intends on becoming a leading green energy company focusing on environmentally friendly opportunities focusing on its leading waste to energy technology and other green industry opportunities existing world-wide.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: CPWR - Compuware Corp.)

LATEST NEWS!!

Compuware Completes Acquisition of Gomez; Customers and Analysts Applaud Strategic Union

Enterprises Benefit From Peerless Capabilities, Unified View for Optimizing Application Performance Across the Enterprise and Internet

DETROIT, Nov 9, 2009 -- Compuware Corporation (Nasdaq:CPWR) today completed its acquisition of Gomez, Inc. Together, Compuware and Gomez deliver an unmatched and unified solution for optimizing application performance across the Enterprise and the Internet. Customers and industry analyst firms have been enthusiastic and positive in their evaluation of the acquisition.

"At AutoTrader.com, we're committed to ensuring top performance for our customers, and we use Compuware and Gomez together to achieve that goal," said Cliff Goolsby, Sr. Director Architecture, Engineering & Systems Assurance. "We use Compuware to gauge responsiveness from inside our enterprise and Gomez to track performance and availability from our customers' point of view, wherever they are on the Internet. We're excited by the vision of integrating the two into the industry's only end-to-end unified view spanning the Enterprise and the Internet." The closure of the $295 million cash transaction brings about 270 new employees to Compuware, including the complete Gomez leadership team. Jaime Ellertson will remain with the organization and serve as President of Gomez, the Web Performance Division of Compuware.

"IDC believes the Gomez/Compuware marriage is a good match with little overlap and lots of upside," wrote Mary Johnston Turner and Tim Grieser of IDC in a report titled Compuware Expands SaaS Portfolio With Gomez Acquisition. "With the completion of the acquisition, Compuware will be able to address a customer's full range of in-house and internet-based application performance management requirements on an end-to-end basis." Compuware will retain the Gomez brand, technology portfolio and business model while moving purposefully to achieve additional technical, sales and marketing synergies. Compuware expects the acquisition to be operationally accretive this fiscal year. The combination of the companies' significant SaaS revenues makes Compuware the world's leading SaaS infrastructure management provider.

According to Jean-Pierre Garbani in the Forrester Blog for Vendor Strategy Professionals, October 7, 2009: "This is a very interesting and potentially game changing move in both the end user experience monitoring and the application performance management (APM) markets." "We're thrilled to welcome the Gomez team to Compuware," said Compuware President and Chief Operating Officer Bob Paul. "Together, Compuware and Gomez will-through a solution that features rapid time-to-value, ease of use and real-time answers-give IT and business executives the optimal application performance they need to drive brand image, customer loyalty and revenue." Gomez, the Web performance division of Compuware, provides the industry's leading platform of Web application experience management solutions used by organizations to optimize the performance, availability and quality of their Web and mobile applications, and proactively identify business-impacting issues. The on-demand Gomez platform integrates solutions for Web load testing, Web performance management, cross-browser testing and Web performance business analysis that test and measure Web and mobile applications from the "outside-in" - across all users, browsers, devices, and geographies - using a global network of over 100,000 locations. Over 2,500 customers worldwide, ranging from small companies to large enterprises - including 12 of the top 20 most visited US Web sites - use Gomez solutions to increase revenue, build brand loyalty, and decrease costs.

For complete information on how this transaction sets the standard for managing the performance of business applications, visit http://www.compuware.com/gomez. Follow us on Twitter at: http://twitter.com/compuware and @Gomez_Inc Compuware Corporation Founded in 1973, Compuware provides software, experts and best practices to ensure applications work well and deliver business value. Compuware solutions optimize application performance across the Enterprise and the Internet for leading businesses around the world, including 46 of the top 50 Fortune 500 companies and 12 of the top 20 most visited U.S. web sites. Learn more at: http://www.compuware.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: CREE - Cree, Inc.)

LATEST NEWS!!

Cree Signs Agreement for Expansion in Huizhou, China

New Chip Production Facility to Help Accelerate LED Lighting Revolution

HUIZHOU, China, Nov 09, 2009 -- Cree, Inc. (Nasdaq: CREE), a market leader in LED lighting, announces an agreement to purchase a 592,000 square foot facility in Huizhou, Guangdong Province, China. The facility will be Cree's first chip production facility outside of North America and is targeted to also house future components manufacturing expansion.

"This investment enables us to expand our presence in China and demonstrates our commitment to serving the growing demands of both our local and global LED customers," said Chuck Swoboda, Cree chairman and CEO. "We are building on a solid foundation in Huizhou with a strong local management team and a history of manufacturing excellence. We look forward to continued success in China as we drive the LED lighting revolution." More than half of Cree's employees work in China, mostly at the current Huizhou factory. Cree recognizes the support of Party Secretary YeBin Huang and Mayor RuQiu Li during the site selection process.

"We are very excited to have Cree's investment in our city. Solid state lighting is a key strategic green industry for China. From the government's perspective, we will do our best to support Cree through government projects as well as government policies. We believe this investment will be a win-win project for Cree and China's SSL industry," said Mr. YeBin Huang, Huizhou's Party Secretary.

Cree also announced that Huizhou is joining the Cree LED City(R) program, an international initiative aimed at promoting the deployment of energy-efficient LED lighting. Huizhou has completed several LED streetlight trials and is in the process of deploying LED streetlights in the ZhongKai Hightech Industrial Zone.

"We are very proud to be the first city in southern China to join the Cree LED City program. Energy saving and emission reduction are our city's priorities for sustainable development; we will continue to drive the adoption of the SSL products through government initiatives," said Huizhou Mayor RuQiu Li.

About Cree Cree is leading the LED lighting revolution and setting the stage to obsolete the incandescent light bulb through the use of energy-efficient, environmentally friendly LED lighting. Cree is a market-leading innovator of lighting-class LEDs, LED lighting, and semiconductor solutions for wireless and power applications.

Cree's product families include LED fixtures and bulbs, blue and green LED chips, high-brightness LEDs, lighting-class power LEDs, power-switching devices and radio-frequency/wireless devices. Cree solutions are driving improvements in applications such as general illumination, backlighting, electronic signs and signals, variable-speed motors, and wireless communications.

For additional product and company information, please refer to www.cree.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: CTXS - Citrix Systems, Inc.)

LATEST NEWS!!

Citrix Makes Virtual Desktops Enterprise Ready by Verifying Over 10,000 Third-Party Products for XenDesktop 4

Over 200 Industry Partners Rally Around the New Citrix XenDesktop 4 as Part of Citrix Ready Open Desktop Virtualization Program

SANTA CLARA, Calif., Nov 09, 2009 -- Citrix Systems, Inc. (NASDAQ: CTXS) today launched the new Citrix Ready(TM) Open Desktop Virtualization program to further accelerate large-scale enterprise virtual desktop deployments with Citrix(R) XenDesktop(TM). The Citrix Ready Open Desktop Virtualization program includes more than 10,000 products from over 200 vendors that have been validated as ready to deploy in production environments with the recently launched XenDesktop 4. The Open Desktop Virtualization program helps make virtual desktops a safe choice for enterprise-wide deployment by eliminating the guess work and ensuring customers that XenDesktop 4 has been tested to work with the software, hardware and services they already uses in their IT environments today. Products that have been verified to work with XenDesktop 4 include thousands of applications, servers, storage systems, backup solutions, client devices, printers, desktop peripherals, security products, desktop management software and systems management solutions.

Launched on October 6, 2009, (see press release) and now available for download, XenDesktop 4, with its unique FlexCast(TM) delivery technology, is the first product in the industry to support every major desktop virtualization model in a single, integrated solution. The FlexCast delivery technology provides the architecture that allows customers to choose from any of the hosted or local virtual desktop delivery models available in one, easy-to-use solution, without locking them into a single, proprietary vendor model. Built with an open architecture, XenDesktop gives customers the flexibility to run heterogeneous environments, lowering costs and maximizing their return on investment. It also makes it easy for customers to gradually add desktop virtualization capabilities at their own pace, simplifying desktop computing, increasing security and enhancing end-user productivity. With its market-leading HDX(TM) technology, XenDestkop 4 also helps ensure that every user has a rich, high-definition experience, regardless of where they are, or what type of device they are using.

"For enterprises to adopt a desktop virtualization platform effectively, they must be able to leverage the existing technologies and networks they have in place. The key being the ability to implement a solution that can address all users without being cost-prohibitive. Desktop virtualization solutions that can address all use cases while still easily integrating with 'any' server virtualization platform and the breadth of add-on technologies should have a lead in driving adoption," said Steve White, program director, Software Alliances Leadership Council, IDC. Citrix continues to make great strides in developing these partnerships across the server, storage, networking, and other complementary technologies. This creates a strong ecosystem giving customers the confidence that a wide range of technologies will work with Citrix solutions." XenDesktop 4 and Citrix Ready Make Desktop Virtualization a Safe Choice Mainstream adoption of desktop virtualization requires a solution that is built with an open architecture and leverages an ecosystem of partner products. This combination helps customers implement an end-to-end solution to enhance or replace their traditional desktop computing environments. XenDesktop 4 supports every major server virtualization platform, including Microsoft Windows Server 2008 Hyper-V(TM), Microsoft Hyper-V Server 2008, Citrix XenServer(TM), VMware ESX(TM) and VMware vSphere. The XenDesktop open architecture further incorporates Citrix Ready and HDX Ready thin clients, Windows, Linux and Mac devices, as well as most major mobile device platforms.

Open Desktop Virtualization Program Ensures Interoperability with Over 10,000 Products The Open Desktop Virtualization program leverages XenDesktop's open architecture and verifies interoperability with over 10,000 products across the following categories:

Datacenter Systems

-- Virtualization Infrastructure -- Hypervisor-based virtualization platforms that host and manage desktops and applications that run in virtual machines. Includes Microsoft Hyper-V, VMware ESX, VMware vSphere and Citrix XenServer

-- Servers and Blade Systems -- Hardware platforms that power server-side virtual desktops and applications running in the datacenter. Includes Dell, HP, IBM, Fujitsu, Intel and AMD

-- Storage and Backup Systems -- Software and hardware storage products that drive increased performance, cost savings and reduced storage requirements for desktop images, user profiles and end-user data. Includes CA, Compellent, CommVault, DataCore, Dell EqualLogic, EMC, FalconStor, Fujitsu, HP StorageWorks, Hitachi, IBM, LSI, NetApp, NEC, Pillar Data Systems, RELDATA and Xiotech

-- Applications -- Enterprise, line-of-business and personal productivity applications that can be delivered more efficiently to end users through desktop and app virtualization. Includes Adobe, Apple, Autodesk, Google, Microsoft, Oracle, SAP and over 1,000 additional software vendors across a wide variety of industries Client Devices

-- PCs, Laptops, Netbooks, Thin Clients and Mobile Devices -- Devices used by employees and other end users to access virtual desktops and applications. Includes Apple, Dell, HP, Lenovo, Fujitsu, Research in Motion (Blackberry), Sprint, 10Zig, Chip PC, Computer Lab, DevonIT, IGEL, ThinLaunch, VXL and Wyse

-- Printers and Desktop Peripherals -- Printing solutions and drivers for an extensive range of cameras, scanners, card readers, hard drives, keyboards, speakers and other popular desktop peripherals that have been certified to work in virtual desktop environments. Includes Canon, Dell, HP, Konica, Kyocera, Lexmark, Mita, Minolta, OKI, Samsung, Xerox, ThinPrint, TriCerat, UniPrint and over 7,000 other popular USB desktop devices and driver support software

-- Unified Communications -- Real-time voice, meeting and communication systems that enable users to collaborate seamlessly over multiple mediums. Includes Avaya, Microsoft, ShoreTel, Citrix GoToMeeting, Citrix Hi-Def Conferencing and Citrix EasyCall Management Systems and Services

-- Client Systems Management -- Unified management of physical endpoint devices to virtual environments providing a consistent cost-effective experience for the desktop administrator. Includes CA Desktop Management Suite for Windows, CA Unicenter, HP OpenView, Microsoft System Center, Novell and Wyse

-- Profile Management -- Software to ensure users' personal settings are applied to the each user's virtual desktop and applications. Includes AppSense, RES Software and TriCerat

-- Security -- Software and hardware products to ensure secure access, business continuity, data security and regulatory compliance for employees working in any type of virtual desktop environment. Includes Kaspersky Labs, McAfee, Novell, RES Software, RSA, Sophos, TrendMicro and Citrix Access Gateway

-- Solution and Deployment Services -- Services to ensure that all users have the best experience when moving to virtual desktops, both for premise based and cloud hosted environments. Includes Accenture, CSC, Dell, HP Services, Fujitsu and IBM Global Services

"Customers who implement a client virtualization strategy are looking for a solution that overcomes the current barriers of high cost and performance bottlenecks," said Paul Miller, vice president, Marketing, Enterprise Storage, Servers and Networking, HP. "HP has a comprehensive portfolio of virtualization-ready solutions that span the desktop to the data center. Together with Citrix and our participation in the Citrix Ready Open Desktop Virtualization program, we ensure customers have successful virtual desktop deployments."

"The Citrix Ready Open Desktop Virtualization program gives customers confidence that third-party products will be verified to work with XenDesktop 4 as they use desktop virtualization technologies to migrate to Windows 7," said Dai Vu, director of virtualization solutions marketing, Server and Tools Business at Microsoft Corp. "As proof of the expanded partnership between Citrix and Microsoft, Hyper-V is distributed with XenDesktop 4 which utilizes Microsoft App-V and Citrix XenApp for hosted and streamed applications, respectively. Now customers enjoy the fastest, simplest way to deliver complete desktop virtualization while maximizing their existing technology investments."

A white paper providing more specific information about the partner categories can be found at the Citrix Ready Open Desktop program page.

For customers new to desktop virtualization and looking to evaluate the interoperability of Open Desktop Virtualization program partner solutions with XenDesktop, they can download the free, easy-to-use XenDesktop Express edition. With XenDesktop Express, customers can set up a 10-user VDI environment and experience HDX technology.

Follow Citrix XenDesktop on the web for the latest news and information at:

-- Citrix XenDesktop 4 page

-- Citrix XenDesktop Community

-- Citrix on Facebook

-- Citrix on Twitter: @XenDesktop and #XD4

About the Citrix Ready Program

The Citrix Ready program identifies verified solutions that are trusted to enhance virtualization, networking and cloud computing solutions from Citrix, including Citrix(R) XenDesktop(TM), XenApp(TM), XenServer(TM), NetScaler(R) and GoToMeeting(R). The Citrix Ready designation is awarded to third party products that have successfully met verification criteria set by Citrix, and gives customers an added confidence in the compatibility of the joint solution offering. The Citrix Ready program leverages industry-leading alliances across the Citrix partner eco-system to meet a wide variety customer needs, and currently incorporates over 2,800 partners who have demonstrated more than 10,000 product verifications. It also includes the Citrix Ready Community Verified program which allows customers to see thousands of products that have been verified by other customers to work in their production environments. The Citrix Ready program received the Alliance Excellence Award from the Association of Strategic Alliance Professionals (ASAP) for creating a strong community of alliances through implementation of new, innovative best practices. More information about the Citrix Ready program can be found on the Citrix website at www.citrix.com/citrixready.

About Citrix Citrix Systems, Inc. (NASDAQ:CTXS) is a leading provider of virtualization, networking and cloud computing solutions for more than 230,000 organizations worldwide. Its Citrix Delivery Center(TM), Citrix Cloud Center(TM) (C3) and Citrix Online product families radically simplify computing for millions of users, delivering desktops and applications as an on-demand service to any user, in any location on any device. Citrix customers include the world's largest Internet companies, 99 percent of Fortune Global 500 enterprises, and hundreds of thousands of small businesses and prosumers worldwide. Citrix partners with over 10,000 companies worldwide in more than 100 countries. Founded in 1989, annual revenue in 2008 was $1.6 billion.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: CYTK - Cytokinetics, Inc.)

LATEST NEWS!!

Cytokinetics Announces Advancement of CK-2017357 in Phase I Clinical Trials

Company Initiates Additional Multi-Dose Trial and 2nd Stage of Ongoing Single-Dose Trial of Novel Skeletal Muscle Activator

SOUTH SAN FRANCISCO, CA, Nov 09, 2009) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the initiation of a double-blind, randomized, placebo-controlled, multiple-dose Phase I clinical trial to investigate the pharmacokinetic profile of CK-2017357. Cytokinetics also announced that the company has initiated the second part, or "Part B", of a previously initiated first-time-in-humans, Phase I clinical trial of CK-2017357 in healthy male volunteers.

"With the initiation of our second Phase I clinical trial and Part B of our ongoing Phase I trial, we expect to gain additional insights into the pharmacokinetics of this novel mechanism drug candidate in healthy volunteers. In addition, we hope to begin to understand the impact this fast skeletal muscle troponin activator may have on the relationship between the force produced by a skeletal muscle and the frequency with which it is stimulated by the motor nerve supplying it, or more simply, the force-frequency relationship," stated Andrew A. Wolff, MD, FACC, Cytokinetics' Senior Vice President of Clinical Research and Development and Chief Medical Officer. "Observations from both of these clinical trials will inform our decisions regarding other metrics to assess in patient populations we intend to study in our Evidence of Effect clinical trials planned for 2010." CK-2017357 is a fast skeletal muscle troponin activator and is the lead drug candidate from the company's skeletal sarcomere activator program. CK-2017357 selectively activates the fast skeletal troponin complex and increases its sensitivity to calcium, leading to an increase in skeletal muscle force. This mechanism of action has demonstrated encouraging pharmacological activity in preclinical models that may relate to the potential treatment of diseases associated with aging, muscle wasting or neuromuscular dysfunction.

Initiation of Multi-Dose Phase I Clinical Trial In this clinical trial, two cohorts of at least 12 healthy male volunteers per cohort will be randomized to receive either CK-2017357 or placebo once daily for seven days. The primary objective of this clinical trial is to determine the safety and tolerability of CK-2017357 after multiple oral doses to steady state in healthy male volunteers. The secondary objective is to evaluate the pharmacokinetic profile of CK-2017357 after multiple oral doses to steady state.

Initiation of Part B in Ongoing Single-Dose Phase I Clinical Trial In June 2009, Cytokinetics initiated the first part, or Part A, of a Phase I, first-time-in-humans, ascending, single-dose, double-blind, placebo-controlled clinical trial of CK-2017357, designed to assess the safety, tolerability, and pharmacokinetic profile of this drug candidate in healthy male volunteers and to determine its maximum tolerated dose and plasma concentration. Cytokinetics continues to dose volunteers in Part A of this trial. Each volunteer participates in two dosing sessions separated by an adequate washout period. Volunteers are randomized (3:1) at the start of each dosing period to receive active study drug or placebo, respectively. Although Part A of the trial is still ongoing and thus remains blinded, to date, no adverse events have been observed in trial participants to indicate that an intolerable dose has been administered. Consequently, the maximum tolerated dose has not yet been determined; however, doses that produced CK-2017357 blood levels associated with increased skeletal muscle function in preclinical models have been tolerated by the healthy volunteers in this study.

The second part, or Part B, of this Phase I clinical trial is a double-blind, randomized, placebo-controlled study of single doses that were tolerated in Part A of this trial. In order to assess the pharmacodynamic effect of CK-2017357 when administered orally to healthy male volunteers, the force-frequency relationship of an externally stimulated nerve-muscle pair and its relationship to CK-2017357 plasma concentration will be determined. A single cohort of volunteers will receive each of three single oral doses of CK-2017357 and oral placebo treatment in a 4-period crossover design; doses will be separated by an adequate washout period. Before and after dosing, the force exerted by the tibialis anterior muscle, measured by a foot flexion device at several different nerve stimulation frequencies, will be determined in order to establish the force-frequency relationship. In preclinical studies measuring this relationship, CK-2017357 appeared to shift the force-frequency curve upward and to the left, with more force being produced at nerve stimulation frequencies in the lower to mid-range of the force-frequency response. This part of the force-frequency response is generally the physiologic range of frequencies at which motor neurons stimulate skeletal muscle during normal function. Part B of this ongoing trial is designed to assess if that effect can be recapitulated in humans.

Background on Skeletal Muscle Activators Skeletal muscle contractility is driven by the sarcomere, the fundamental unit of skeletal muscle contraction. It is a highly ordered cytoskeletal structure composed of several key proteins. The first, skeletal muscle myosin, is the cytoskeletal motor protein that converts chemical energy into mechanical force through its interaction with a second protein, actin. A set of regulatory proteins, which includes tropomyosin and three troponin subunits, make the actin-myosin interaction dependent on changes in intracellular calcium levels. Cytokinetics' skeletal muscle contractility program is focused to the discovery and development of small molecule skeletal sarcomere activators and leverages Cytokinetics' expertise gained from its ongoing discovery and development of cardiac sarcomere activators, including the cardiac muscle myosin activator, omecamtiv mecarbil, now in Phase II clinical development as a potential treatment for heart failure. In non-clinical models, skeletal sarcomere activators have demonstrated pharmacological activity that may lead to new therapeutic options for diseases associated with aging, muscle wasting or neuromuscular dysfunction. The clinical effects of muscle wasting, fatigue and loss of mobility can range from decreased quality of life to, in some instances, life-threatening complications. By directly improving skeletal muscle function, a small molecule activator of the skeletal sarcomere may potentially enhance physical performance and quality of life in patients with conditions marked by muscle weakness, including neuromuscular diseases such as amyotrophic lateral sclerosis (ALS) and myasthenia gravis, and other diseases and syndromes such as sarcopenia, claudication, cachexia, and the general frailty associated with aging.

Market Potential for Skeletal Muscle Activators The conditions that could benefit from a skeletal muscle activator are grievous and severe. Few options exist for the treatment of ALS, which afflicts between 20,000 and 30,000 people in the United States, and is associated with a 3-year mortality rate of 50%. Another neuromuscular disorder, myasthenia gravis, a chronic disease characterized by a defect in the transmission of nerve impulses to skeletal muscles, afflicts approximately 60,000 patients in the United States. Patients with disorders and conditions with a higher prevalence could also benefit from enhanced skeletal muscle functional performance, including patients with cachexia, intermittent claudication and sarcopenia. Cachexia, a syndrome characterized by a drastic and unintentional loss of body mass, is estimated to be prevalent in 15%-35% of heart failure patients and in approximately 50% of cancer patients. Intermittent claudication, which usually refers to cramping pains in the legs caused by peripheral arterial disease, is a condition that impacts between 1 million and 3 million people in the United States each year. Sarcopenia, which is an age-related loss of muscle mass, strength, and function, is estimated to impact the lives of over 25-30% of the U.S. population over the age of 65 and can result in additional injuries and medical conditions due to limited mobility.

About Cytokinetics Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is in Phase I clinical development. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions such as systemic hypertension, pulmonary arterial hypertension or bronchoconstriction. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates in Phase I clinical development: ispinesib, SB-743921 and GSK-923295. Cytokinetics is seeking a partner for ispinesib and SB-743921 and GSK-923295 is being developed under Cytokinetics' collaboration with GlaxoSmithKline. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: DGII - Digi International Inc.)

LATEST NEWS!!

Digi Console Server Earns Security Certification for Government and Other Regulated Industry Applications

Digi Passport Receives NIST FIPS 140-2 Certification

MINNETONKA, Minn., Nov 09, 2009 -- Digi International (NASDAQ: DGII) today announced that it has received Federal Information Processing Standard (FIPS) 140-2 Level 2 security certification for the Digi Passport console server from the National Institute of Standards and Technology (NIST). This stringent third-party security certification makes the Digi Passport ideal for data center management in government, healthcare, financial and other regulated industries.

"FIPS certification is accepted globally as one of the most trusted security validations," said Steve Mazur, director of government sales, Digi International. "Many U.S. government agencies can only purchase security products that have received FIPS 140-2 certification, and other regulated industries also require it. This certification greatly expands the markets in which the Digi Passport can be used." "The FIPS 140-2 validation process is a time consuming and complex task," said Eugene Polulyakh, technical manager of Aspect Labs, a third-party government accredited FIPS testing lab. "Companies that achieve FIPS 140-2 certification must meet numerous stringent security requirements as defined by the NIST. Customers using FIPS 140-2 certified products can be confident they have chosen a technology that was independently tested to ensure compliance with advanced cryptographic and security standards." The Digi Passport console server is a powerful data center management device that combines console management, IPMI and remote KVM functionality in one box. Designed to reduce workload on data center managers, the Digi Passport provides secure remote access for computer systems and network equipment. It supports serial console connections, service processor connections to the leading server vendors, as well as SMASH extensions to network-based access protocols. Capable of communicating with virtually any server or device, the Digi Passport is ideal for cross-platform equipment support.

To further support government agencies, Digi also launched www.digigovsales.com. The Website offers product information, application descriptions and technical resources specifically for government agencies.

The Digi Passport is available now in FIPS mode in four, eight, 16, 32 and 48 port models. For more information, please visit www.digi.com/products/consoleservers/digipassport.jsp#overview.

About Digi International Digi International is making wireless M2M easy by developing reliable products and solutions to connect and securely manage local or remote electronic devices over the network or via the Web. Digi offers the highest levels of performance, flexibility and quality, and markets its products through a global network of distributors and resellers, systems integrators and original equipment manufacturers (OEMs). For more information, visit Digi's Web site at www.digi.com, or call 877-912-3444.

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com e-mail: info@StockMarketingInc.com Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: acquisition, adoption, architecture, asia, belize, business, california, canada, cancer, ceo, china, clinical, communications, community, computer, corporate, disease, distributor, electrical, email, e-mail, energy, engineering, environment, expansion, federal, fertilizer, government, guangdong, hardware, healthcare, india, industrial, internet, investment, investment opinion, japan, linux, local, manufacturing, market, marketing, marriage, medical, minnesota, nasdaq, natural resources, networking, north america, online, partnership, peripherals, population, president, productivity, products, radio, research, research and development, revenue, sales, security, semiconductors, software, standards, technology, track, trial, unions, utilities, web, wireless